Medtronic Licensing Deal With Abbott Is Hawkins’ First Test: Results Pending
This article was originally published in The Gray Sheet
Executive Summary
William Hawkins' initial stamp on Medtronic's struggling AVE vascular business includes a licensing deal with Abbott Laboratories for a drug-eluting stent compound and an unrelated restructuring of the operating unit, both announced May 9